CDK1/2/5 blockade: killing two birds with one stone.

Pancreatic ductal adenocarcinoma (PDAC) is an immune resistant tumor. We recently demonstrated that inhibiting CDK1/2/5 by dinaciclib not only blocks immune checkpoint expression, but also triggers histone-dependent immunogenic cell death. This dual mechanism turns immunologically "cold" tumor microenvironment into a "hot" one, improves overall survival rates in mouse PDAC models.